Summary of Jasper Therapeutics Chronic Urticaria Data Update Webinar Company Overview - **Company**: Jasper Therapeutics (NasdaqCM: JSPR) - **Focus**: Development of briquilimab for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) Key Points and Arguments Industry and Product Development - **Briquilimab**: An antibody targeting the KIT receptor, showing promise in treating mast cell-driven diseases, including CSU and CIndU [4][5] - **Clinical Trials**: Updated data from the BEACON study and an open-label extension study were presented, indicating positive outcomes for briquilimab [4][5] Efficacy and Safety Data - **BEACON Study Results**: - Six out of eight patients receiving briquilimab achieved complete response (CR) by week three, and four out of six by week 12 [6][9] - Mean reduction of UAS7 scores was 31 points at week 12, indicating significant symptom relief [9][12] - Rapid onset of disease control was observed, with most patients showing improvement within two weeks [9][10] - **Open-Label Extension Study**: - 63 patients treated with briquilimab showed durable clinical responses, with 65% of CIndU patients achieving CR or partial response (PR) at week 16 [9][15] - A favorable chronic safety profile was reported, with low incidence of KIT-related adverse events [7][20] Future Plans - **Phase 2b Study**: - Expected to commence in the second half of 2026, involving 75 to 100 adult patients with CSU [8][20] - The study will evaluate two effective dose regimens versus placebo [20] - **Dose Selection**: - Ongoing analysis of current data will inform the final dose selection for the phase 2b study [24][55] - Consideration of weight-adjusted dosing to optimize efficacy [48][55] Competitive Positioning - **Differentiated Product Profile**: - Briquilimab's unique mechanism of action and favorable safety profile position it competitively against other therapies targeting the KIT receptor [18][19] - The company believes the data supports a compelling product profile for chronic urticarias [20] Financial Considerations - **Capital Requirements**: - Current capital is sufficient to support operations through mid-2026, but additional funding will be necessary for future studies [28] - **Partnership Opportunities**: - The company is open to potential partnerships to support broader development across multiple indications [34] Additional Important Information - **CEO Transition**: The change in leadership was driven by the need for a new direction as the company progresses into pivotal studies [24] - **Regulatory Considerations**: The company is preparing to engage with regulatory bodies regarding the phase 2b study design and dose selection [25][46] This summary encapsulates the critical insights from the Jasper Therapeutics webinar, highlighting the company's advancements in chronic urticaria treatment and future strategic directions.

67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks With a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study BEACON and o ...

Company Leadership Changes - Jasper Therapeutics has appointed Jeet Mahal as President and Chief Executive Officer, effective January 5, 2026, succeeding Ronald Martell [2][3] - Thomas Wiggans has been appointed as the Executive Chairperson of the Board of Directors [2][3] Strategic Focus and Development - The company is preparing to commence the registrational program for briquilimab, targeting mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) [3][4] - Mr. Mahal brings over thirty years of experience in the life sciences industry, with a focus on developing therapeutics and leading biotech companies through clinical trials [3][4] Upcoming Events - Jasper will host an investor webinar on January 8, 2026, at 8:00 a.m. ET to present updated data from the BEACON study and the open-label extension study in CSU and CIndU [2][5] - A live question and answer session will follow the formal presentation during the webinar [5][6] Product Development - Briquilimab is a targeted monoclonal antibody that inhibits signaling through the KIT receptor, aiming to deplete mast cells and address inflammatory responses in diseases like CSU and asthma [7][8] - The drug has shown efficacy and safety in clinical studies involving patients and healthy volunteers, with positive outcomes reported in CSU, CIndU, and allergic asthma [8]

Summary of Jasper Therapeutics Data Update Webinar Company Overview - **Company**: Jasper Therapeutics (NasdaqCM:JSPR) - **Date of Call**: December 2, 2025 Key Points Industry and Company Focus - **Industry**: Biotechnology, specifically focusing on treatments for chronic spontaneous urticaria (CSU) and allergic asthma - **Core Product**: Briquilimab, a drug targeting mast cells BEACON Trial Findings - **Unexpected Results**: In the BEACON trial for CSU, none of the 10 U.S. patients in Cohort 8 achieved complete response by week 12, contrasting with two out of three patients in EU sites who did respond, indicating potential issues with drug lot A34954 used in the U.S. [4][5] - **Investigation**: An internal investigation was launched, reviewing manufacturing records, drug handling, and patient data. No significant deviations were found in drug production or handling [5][10][11]. - **Patient-Specific Factors**: The investigation concluded that patient-specific factors likely caused the unexpected results, with many patients possibly not having CSU [11][17]. Redosing Data from BEACON - **Cohorts 8 and 9**: Patients were switched to a new drug lot (34955) during the trial, showing no changes in pharmacokinetics (PK) or pharmacodynamics (PD) measures after redosing [12][15]. - **Clinical Outcomes**: The drug effectively depleted mast cells, as indicated by reduced tryptase levels, but clinical responses were not observed in many patients, suggesting misdiagnosis [15][17]. ATESIAN Study Results - **Study Design**: The ATESIAN trial assessed briquilimab's safety and efficacy in patients with mild allergic asthma, focusing on allergen challenges [20][21]. - **Efficacy Observations**: A single 180 mg dose resulted in significant reductions in serum tryptase levels and improved FEV1 responses, indicating a sustained effect on both early and late asthmatic responses [22][24]. - **Safety Profile**: Briquilimab was well tolerated with no serious treatment-related adverse events reported, reinforcing its safety in asthmatic populations [24][26]. Future Directions - **Next Steps**: Jasper plans to report additional BEACON data and open-label extension data in Q1 2026, including efficacy and safety data from new patients [26][27]. - **Broader Asthma Studies**: The company is evaluating further studies to explore briquilimab's effects across different asthma endotypes, including T2 high and T2 low diseases [25][27]. Recommendations for Future Trials - **Patient Selection**: Emphasis on quality patient selection is crucial, with recommendations to involve certified specialists in diagnosing CSU to avoid misdiagnosis [18][49]. - **Larger Sample Sizes**: Increasing sample sizes in trials may help mitigate the impact of non-mast cell-driven patients [18][67]. Conclusion - **Overall Outlook**: Jasper Therapeutics is optimistic about briquilimab's potential in treating both CSU and asthma, with ongoing investigations and upcoming data expected to support its clinical efficacy and safety [72].

Core Insights - Jasper Therapeutics reported positive preliminary clinical data from the ETESIAN Phase 1b study of briquilimab, showing significant reductions in airway hyperresponsiveness and eosinophilic response in asthma patients [2][4][5] Group 1: ETESIAN Study Findings - A single subcutaneous 180mg dose of briquilimab resulted in substantial reductions in sputum eosinophils at both 6 weeks (1.88% to 0.44%) and 12 weeks (1.88% to 0.38%) [2][12] - Improvements in FEV1 were observed in both Early Asthmatic Response (EAR) and Late Asthmatic Response (LAR), with LAR %Max FEV1 improving by 10.4% at 6 weeks and 8.7% at 12 weeks compared to baseline [7][10] - The study demonstrated a favorable safety profile for briquilimab, with no dose-limiting toxicities and infrequent low-grade adverse events [14] Group 2: BEACON Study Investigation - Jasper completed an internal investigation into the lack of clinical response in the BEACON study, concluding that the unexpected results were likely due to patient selection issues rather than problems with the drug product [3][16] - The investigation revealed that 9 out of 10 patients did not have chronic spontaneous urticaria (CSU) as their symptoms were not mast cell-driven, which affected the efficacy results [16][17] - The company is confident that insights from this investigation will help minimize enrollment of patients without mast cell-driven diseases in future studies [17] Group 3: Future Developments - Jasper plans to further develop briquilimab for asthma treatment, supported by the positive data from the ETESIAN study and the favorable safety profile observed [4][20] - The company anticipates additional data from the BEACON study in Q1 2026, which will inform dose selection for the Phase 2b CSU study planned for mid-2026 [17][20]

Core Viewpoint - Jasper Therapeutics is hosting a webinar to discuss findings from the BEACON study and preliminary data from the ETESIAN study, focusing on briquilimab's potential in treating mast cell driven diseases [1][2] Group 1: Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, an antibody therapy targeting c-Kit (CD117) for chronic mast cell diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [3] - Briquilimab works by blocking stem cell factor from binding to the KIT receptor, leading to mast cell depletion and reducing inflammation associated with these diseases [3] - The company has demonstrated efficacy and safety of briquilimab in clinical studies involving patients and healthy volunteers, showing positive outcomes in CSU and CIndU [3] Group 2: Webinar Details - The webinar is scheduled for Tuesday, December 2, 2025, at 8:00 am ET, featuring presentations from Jasper management and Dr. Martin Metz, a leading investigator in the BEACON study [1][2] - A live Q&A session will follow the formal presentation, allowing for direct engagement with the audience [1]

Core Insights - Bragar Eagel & Squire, P.C. is investigating officers and directors of Driven Brands Holdings, Inc. and Jasper Therapeutics, Inc. on behalf of long-term stockholders due to class action complaints filed against both companies [1][4] Driven Brands Holdings, Inc. (NASDAQ: DRVN) - A class action complaint was filed against Driven Brands on December 22, 2023, alleging that the company made materially false and misleading statements regarding its ability to integrate acquired businesses and the performance of its car wash segment [2][3] - The complaint claims that Driven Brands misrepresented its integration capabilities as a "core strength" and assured investors of "significant progress" in integrating its U.S. auto glass businesses, while downplaying issues related to customer demand in its car wash segment [3] Jasper Therapeutics, Inc. (NASDAQ: JSPR) - A class action complaint was filed against Jasper Therapeutics on September 19, 2025, alleging that the company made materially false and misleading statements about its business operations and compliance policies [4][5] - The complaint highlights that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which increased risks for ongoing studies and overstated the company's financial and clinical prospects [5]

Core Viewpoint - Rosen Law Firm is encouraging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and failures in manufacturing compliance [1][5]. Group 1: Legal Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Jasper Therapeutics - The lawsuit claims that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations, which could negatively impact the clinical and commercial prospects of its products, including briquilimab [5]. - The alleged failures increased the risk of confounding results in ongoing studies and the likelihood of disruptive cost-reduction measures, leading to overstated business and financial prospects [5].

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with deadlines for filing lead plaintiff motions set for November 18, 2025 [1] Quanex Building Products Corporation (NYSE: NX) - Class period spans from December 12, 2024, to September 5, 2025, with allegations of materially false and misleading statements made by defendants [2] - Key issues include significant underinvestment in tooling and equipment maintenance at the Tyman Mexico facility, leading to degraded conditions and potential significant costs that could delay expected benefits from the Tyman integration [2] Jasper Therapeutics, Inc. (NASDAQ: JSPR) - Class period runs from November 30, 2023, to July 3, 2025, with similar allegations of misleading statements and undisclosed adverse facts [3] - Defendants failed to disclose lack of necessary controls for third-party manufacturers, increasing risks to ongoing studies and overstating the company's business and financial prospects [3] KBR, Inc. (NYSE: KBR) - Class period is from May 6, 2025, to June 19, 2025, with allegations of misleading statements regarding the partnership with TRANSCOM and its ability to fulfill contracts [5] - Defendants claimed no issues with the partnership despite known material concerns, leading to misleading statements about the company's operations and prospects [5]

Core Viewpoint - Rosen Law Firm is urging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and failures in manufacturing compliance [1][5]. Group 1: Legal Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record in securities class actions, highlighting its own success in recovering significant settlements for investors [4]. Group 2: Allegations Against Jasper Therapeutics - The lawsuit claims that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations, which could negatively impact the clinical and commercial prospects of its products, particularly briquilimab [5]. - The alleged failures increased the risk of confounding results in ongoing studies and overstated the company's business and financial prospects [5].